Adriamycin
Monoclonal Gammopathy
Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Moderate confidence
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Monoclonal Gammopathy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Adriamycin (this asset) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | P3 | BB · 64 |
| Dexasone | Hellenic Society of Hematology | P3 | BB |
| Liraglutide | University of Miami | P4 | BB |
| (+)-Vincristine | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | P3 | B |
| Daratumumab | Hellenic Society of Hematology | P2 | B |
| Pomalidomide | Hellenic Society of Hematology | P1/2 | CC |
| Belantamab Mafodotin | Hellenic Society of Hematology | P1/2 | CC |
| Lenalidomide | Hellenic Society of Hematology | P1/2 | CC |
| Nirogacestat | Hellenic Society of Hematology | P1/2 | CC |
+3 more in the Monoclonal Gammopathy cohort
Other indications for Adriamycin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 77 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 76 |
| Hematopoietic And Lymphoid System Neoplasm | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Adriamycin in Monoclonal Gammopathy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/adriamycin-monoclonal-gammopathy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →